Drug Update · Hematology

FDA Approves imetelstat for LR-MDS: 40% 8-week RBC-TI in IMerge

July 10, 2026

Primary endpoint

8-week RBC-TI 40% (imetelstat) vs 15% (placebo) [1]

Trial

IMerge, randomized, double-blind, placebo-controlled, phase 3 [1]

Enrollment

178 patients randomized (118 imetelstat, 60 placebo) [1]

FDA approval date

2024-06-06 (original approval date listed) [12][2]

Approved dose

7.1 mg/kg IV infusion every 4 weeks (RYTELO labeling) [7][12]

Clinical Perspective

This approval affects hematologists, oncologists, transfusion medicine specialists, and advanced practice providers caring for adults with low- to intermediate-1 risk MDS who are transfusion-dependent and have not responded to or are ineligible for ESAs. The IMerge data support use of imetelstat to achieve transfusion independence, with 40% of treated patients achieving ≥8-week RBC-TI versus 15% with placebo in the randomized trial. How clinicians will integrate imetelstat given the high rates of grade 3-4 cytopenias and monitoring requirements remains a key practical question?

Dr. Shruti Pandey, MBBS, MD (General Medicine), DM (Clinical Haematology) · Hematology

The FDA approved imetelstat (RYTELO) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who are ESA-relapsed, ESA-refractory, or ESA-ineligible ^[4]^[5]. Approval was based on the phase 3 IMerge trial, which showed 47 (40% [95% CI 30.9-49.3]) patients receiving imetelstat achieved an 8-week red blood cell transfusion independence (RBC-TI) versus nine (15% [7.1-26.6]) with placebo (rate difference 25% [9.9 to 36.9]; p=0.0008) ^[1]^[5].

Clinical Context

Imetelstat is an oligonucleotide telomerase inhibitor developed by Geron Corporation and approved under the brand name RYTELO for transfusion-dependent low- to intermediate-1 risk MDS ^[4]^[5]. The drug is administered by intravenous infusion and was evaluated in a population who had not responded to or were ineligible for erythropoiesis-stimulating agents (ESAs) ^[1]^[4]. The approval targets adults with anemia requiring frequent RBC transfusions (≥4 units over 8 weeks). Clinicians should consult current prescribing information for full dosing guidance. The IMerge dataset and the FDA review contributed to labeling that includes dosing, monitoring, and warnings for hematologic toxicity and infusion-related reactions ^[1]^[3]^[4]^[5].

Key Findings

IMerge showed imetelstat achieved an 8-week RBC transfusion independence rate of 40% versus 15% with placebo (rate difference 25% [9.9 to 36.9]; p=0.0008) ^[1].
In IMerge (randomized 2:1), 178 patients were enrolled (118 imetelstat, 60 placebo) and efficacy analyses were based on the intention-to-treat population; median follow-up was 19.5 months (IQR 12.0-23.4) in the imetelstat group and 17.5 months (IQR 12.1-22.7) in the placebo group ^[1]^[5].
The trial also reported longer RBC-TI durability: 33 (28.0%) imetelstat patients achieved ≥24-week RBC-TI versus two (3.3%) with placebo (rate difference 24.6%; 95% CI 12.6, 34.2; p<0.001) ^[5]^[1].

Safety & Tolerability

Grade 3-4 treatment-emergent adverse events occurred in 107 (91%) of 118 patients receiving imetelstat versus 28 (47%) of 59 receiving placebo in IMerge ^[1].
Neutropenia: 80 patients (68%) who received imetelstat experienced neutropenia versus two (3%) in the placebo arm ^[1].
Thrombocytopenia: 73 patients (62%) who received imetelstat experienced thrombocytopenia versus five (8%) in the placebo arm ^[1].
Other laboratory and clinical events named in the prescribing information include decreased platelets, decreased white blood cell counts, decreased neutrophil counts, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache ^[4]^[5].
Infusion-related reactions occurred in 8% of patients in the trial; Grade 3-4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%) ^[4]^[5].
In the trial report, no treatment-related deaths were reported; rates of febrile neutropenia and sepsis are listed in the label (febrile neutropenia 0.8%; sepsis 4.2%) ^[1]^[4]^[5].

Study Design

IMerge was a multinational, randomized, double-blind, placebo-controlled, phase 3 trial that enrolled 178 patients with ESA-relapsed, ESA-refractory, or ESA-ineligible low- or intermediate-1 risk MDS; patients were randomized 2:1 to receive imetelstat or placebo until progression, unacceptable toxicity, or consent withdrawal ^[1]^[5]. The primary endpoint was 8-week RBC transfusion independence (absence of RBC transfusions for at least 8 consecutive weeks from randomization). The FDA approved imetelstat (RYTELO) for the specified transfusion-dependent LR-MDS indication based on these results ^[2]^[4]^[5].

FAQ

Q1 What is imetelstat (RYTELO) approved for?

Imetelstat (RYTELO) is approved for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks and who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). The approval is based on the phase 3 IMerge randomized trial demonstrating higher rates of transfusion independence compared with placebo. Clinicians should consult current prescribing information for full dosing guidance.

Q2 How does imetelstat work?

Imetelstat is an oligonucleotide telomerase inhibitor that binds to the RNA template component of human telomerase, inhibiting telomerase enzymatic activity and preventing telomere elongation. Nonclinical studies reported reductions in telomere length, decreased malignant stem and progenitor cell proliferation, and induction of apoptotic cell death; these mechanisms underlie its investigational disease-modifying effects in MDS.

Q3 What is the recommended dose of imetelstat?

The FDA-approved dosage of RYTELO is 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks for eligible adults with transfusion-dependent low- to intermediate-1 risk MDS. The prescribing information specifies monitoring schedules and dose modification rules for hematologic and non-hematologic toxicities. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the side effects clinicians should monitor for?

The most prominent toxicities observed and described in the labeling and IMerge publication are cytopenias and infusion-related reactions. In IMerge, grade 3-4 treatment-emergent adverse events occurred in 107 (91%) of imetelstat-treated patients versus 28 (47%) with placebo; neutropenia occurred in 80 (68%) imetelstat patients versus two (3%) placebo, and thrombocytopenia in 73 (62%) imetelstat patients versus five (8%) placebo. The label also lists decreased platelets, decreased white blood cells, decreased neutrophils, increased AST/ALT/alkaline phosphatase, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, headache, COVID-19 infections, infusion-related reactions (including rare hypertensive crisis), febrile neutropenia, and sepsis. Monitoring complete blood counts at the recommended intervals and following dose modification guidance are required. Clinicians should consult current prescribing information for full dosing guidance.

FDA Approves imetelstat for LR-MDS: 40% 8-week RBC-TI in IMerge

FDA Approves imetelstat for LR-MDS: 40% 8-week RBC-TI in IMerge

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Hematology in your inbox.

Verified HCP Portal